Bal Pharma
- Market cap
- ₹ 131 Cr.
- P/E
- 19.1x
- P/B
- 1.64x
- 52-week range
- 60 – 124.6
- ROE
- 8%
- ROCE
- 10%
- Dividend yield
- 1.4%
- Debt / equity
- 2.03
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Bal Pharma Limited is a pharmaceutical company engaged in the manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It specializes in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers a range of APIs including antihistamine, platelet inhibitor, anti-diabetic, anticonvulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers a range of formulations covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmics, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Bal Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.1 against a typical 34: cheaper than most peers (1st = cheapest).52nd of 220
- Sales growth+34.5% against a typical +15.6% from a year earlier.47th of 197
- Profit growth+438.1% against a typical +18.9% from a year earlier.10th of 160
- Share price, 3 months−5.7% against a typical −0.5%.128th of 200
- Size₹ 130.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).136th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB- by Acuite- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Acuite | ACUITE BBB- | Stable | 28 Aug 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 28 Aug 2026 | Reaffirmed | ACUITE BBB- | — | Acuite | ₹ 200 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 12 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 27 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the audited financial results for the period ended March 31, 2026, dividend and other business matters |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 12 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 11 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 29 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 93 | 82 | 95 | 74 | 74 | 73 | 82 | 66 | 74 | 88 | 84 | 89 |
| Expenses | 85 | 74 | 85 | 68 | 66 | 65 | 74 | 60 | 68 | 78 | 74 | 81 |
| Operating Profit | 8 | 8 | 10 | 6 | 8 | 8 | 8 | 6 | 6 | 10 | 11 | 8 |
| OPM % | 8.3% | 9.5% | 10.1% | 8.7% | 10.4% | 10.6% | 9.3% | 9.2% | 7.7% | 10.9% | 12.6% | 9% |
| Other Income | 0 | 0 | 2 | 1 | −0 | 1 | 1 | 1 | 1 | 0 | −0 | 0 |
| Interest | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 |
| Depreciation | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 3 | 3 | 3 |
| Profit before tax | 2 | 1 | 6 | 1 | 1 | 1 | 3 | 0 | 1 | 2 | 3 | 1 |
| Tax % | 39.4% | 33.1% | 3.7% | 58.1% | 23.5% | 7.1% | −108.9% | 0% | 0% | 0% | −12.1% | 0% |
| Net Profit | 1 | 1 | 6 | 0 | 1 | 1 | 5 | 0 | 1 | 2 | 4 | 1 |
| EPS in Rs | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.3 | 3.41 | 0.13 | 0.45 | 1.12 | 2.25 | 0.7 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 5%
- 5 Years
- 4%
- 3 Years
- 1%
- TTM
- 14%
- 10 Years
- 16%
- 5 Years
- 6%
- 3 Years
- 35%
- TTM
- 1%
- 10 Years
- 0%
- 5 Years
- −2%
- 3 Years
- −2%
- TTM
- —
- 10 Years
- 5%
- 5 Years
- 8%
- 3 Years
- 9%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Bal Pharma | ₹ 107.47 | ₹ 131 Cr. | 19.1x | 1.6x | 8% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Akash Mathur
- Chief Executive Officer
- Shreepada M. L.
- Compliance Officer, Company Secretary
- Shailesh D. Siroya
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.